首页> 外文期刊>Current Medicinal Chemistry >Inhibitors of Multidrug Resistance to Antitumor Agents (MDR)
【24h】

Inhibitors of Multidrug Resistance to Antitumor Agents (MDR)

机译:多种抗肿瘤药耐药性抑制剂(MDR)

获取原文
获取原文并翻译 | 示例
       

摘要

Multidrug resistance is one of the main obstacles in the chemotherapy of cancer. Its inhibition by combination of chemosensitizers with antitumor compounds is a very active field of research, since safe and potent reversal agents would be beneficial for clinical use. Most modulators act by binding to membrane transport proteins (specially P-gp and MRP) and inhibiting their drug-effluxing activity, or by indirect mechanisms related to phosphorylation of the transport proteins or expression of the mdr1 and mrp1 genes. The main body of the review focuses on the study of the known MDR modulators, which are classified according to their chemical structures. General structure-activity studies of this therapeutic group are hampered by the very heterogeneous chemical structure of the compounds, although some conclusions have been drawn from the study of homogeneous series of molecules.
机译:多药耐药性是癌症化学疗法的主要障碍之一。通过化学增敏剂与抗肿瘤化合物的组合来抑制其作用是一个非常活跃的研究领域,因为安全有效的逆转剂对临床应用将是有益的。大多数调节剂通过与膜转运蛋白(特别是P-gp和MRP)结合并抑制其药物外排活性,或通过与转运蛋白磷酸化或mdr1和mrp1基因表达相关的间接机制起作用。综述的主体侧重于对已知MDR调节剂的研究,这些调节剂根据其化学结构进行分类。该化合物的非常不均一的化学结构阻碍了该治疗组的一般结构活性研究,尽管从均质系列分子的研究中得出了一些结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号